Document is current

Article History

Received: 29 September 2025

Accepted: 5 December 2025

First Online: 20 December 2025

Declarations

:

: Mark G. Lebwohl is an editorial board member of Dermatology and Therapy . Mark G. Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Mark G. Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Arcutis Biotherapeutics, Avotres, Boehringer Ingelheim, Cara Therapeutics, Clexio Biosciences, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Johnson & Johnson, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Aikium, Almirall, AltruBio, Amgen, Apogee, Arcutis Biotherapeutics, AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, Dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Mayne Pharmaceuticals, Meiji Seika Pharma, Mindera, Mirium Pharmaceuticals, Oruka, Pfizer, Sanofi-Regeneron, Revolo, Seanergy, Strata, Sun Pharma, Takeda, Trevi, and Verrica. Darrell S. Rigel is a consultant for and has received honoraria and advisory board fees from Beiersdorf, Castle Biosciences, Kenvue, Pfizer, Regeneron Pharmaceuticals, and Sun Pharma. Zeynep Eroglu reports advisory board fees from Eisai, Genentech, Natera, Novartis, OncoSec, Pfizer, and Regeneron Pharmaceuticals; and research grants from Boehringer Ingelheim, Novartis, and Pfizer. Victoria E. Barghout is CEO of Viver Health LLC, which receives funding from Sun Pharma. Deepshekhar Gupta, Enrico Zanardo, Lynn Huynh, and Mihran A. Yenikomshian are employees of Analysis Group, Inc., which received research funding from Sun Pharma to conduct the study. Kunal Patel and Nicholas Squittieri are employees of Sun Pharmaceutical Industries, Inc. Thomas J. Ferro was an employee of Sun Pharmaceutical Industries, Inc., at the time of the study.

: This study was conducted as secondary research using deidentified data licensed from a third party, Komodo, after obtaining permission to use the database and in compliance with 45 CFR 164.514(a)–(c). No direct subject contact or primary collection of individual human subject data occurred. Study results are reported in tabular form and as aggregate analyses that omit subject identification; therefore, informed consent and ethics committee or institutional review board (IRB) approval were not required.